Anupam Verma

Employment

• Rainbow Babies & Children's Hospital Professor
  2026 - Present
• Case Western Reserve University Professor
  2026 - Present
• Children's National Hospital Center for Cancer and Blood Disorders
  2023 - 2026
• Inova Children's Hospital
  2023 - 2026
• National Institutes of Health Associate Research Physician
  2022 - 2023
• University of Utah Associate Professor
  2012 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (29)

• Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025017837
  +Save
• Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial
  Pediatric Blood & Cancer 2025 DOI: 10.1002/pbc.31584
  +Save
• Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial
  Blood Advances 2024 DOI: 10.1182/bloodadvances.2024014415
  +Save
• Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
  Cancers 2024 DOI: 10.3390/cancers16030496
  +Save
• Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
  Blood Advances 2023 DOI: 10.1182/bloodadvances.2022009381
  +Save
• Management of Down Syndrome-Associated Leukemias: A Review.
  JAMA oncology 2023 DOI: 10.1001/jamaoncol.2023.2163
  +Save
• Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study
  Leukemia 2023 DOI: 10.1038/s41375-023-01856-6
  +Save
• A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
  Blood 2023 DOI: 10.1182/blood.2022015797
  +Save
• Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia.
  Infection control and hospital epidemiology 2022 DOI: 10.1017/ice.2022.82
  +Save
• Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
  JAMA 2022 DOI: 10.1001/jama.2021.23182
  +Save